2023 / 04 / 07
Exhibition and Presentation at
CPHI Japan 2023
Ajinomoto Bio-Pharma Services will participate in CPHI Japan, on April 19 to 21, 2023.
CPHI Japan is the ideal business platform for international pharma professionals to join in order to grow their business in the rapidly evolving Japanese pharma market. Hosting over 420 exhibitors from ingredients, contract services and biopharma through to technology, packaging and machinery.
Ajinomoto Bio-Pharma Services will be making presentations, and exhibiting its services and technologies at the conference.
At the exhibition booth, the latest technologies and services such as AJIPHASE®, AJICAP®, CORYNEX®, and TALAMAX® will be introduced.
In addition, the latest technologies and services of AJICAP®, a site-specific conjugation technology, and CORYNEX®/TALAMAX®, a microbial platform for peptide, protein and antibody production, will be presented at the exhibitors’ presentations.
We look forward to your visit.
|Event Name||CPHI Japan 2023|
|Dates||April 19(Wed) – 21 (Fri), 2023|
|Venue||Tokyo Big Sight|
|Exhibition||Booth : Bio Pharma 6B-08
|Title and Presenters||“Next generation antibody modification platform AJICAP®
-Chemical site-specific conjugation & novel ADC linker technology-”
Tomohiro Fujii, Research Institute for Bioscience Products & Fine Chemicals, Ajinomoto Co., Inc.
|Executive Summary||Antibody-drug conjugates (ADCs) are promising biopharmaceuticals in which payload is added to an antibody. Recently, site-specific ADCs are expected to improve drug efficacy and reduce toxicity compared to existing random conjugated ADCs. In this presentation, we will introduce AJICAP®, a site-specific conjugation technology in ADC field.|
|Date, Time and Venue||April 21(Fri.) 14：00-14：30 【5B】|
|Title and Presenters||“One-stop-shop service for peptide/protein manufacturing by AJINOMOTO’s unique expression platform technologies CORYNEX® and TALAMAX®”
Mitsunori Tokura, Bio-pharma services dept., Ajinomoto Co., Inc.
|Executive Summary||CORYNEX® is an endotoxin-free microbial secretory expression technology for the production of proteins, especially suitable for the production of VHH, antibody mimetics and long-chain peptides. In addition, we have developed a new technology to incorporate non-canonical amino acids at a site client choice in target protein, which enables the production of proteins that can conjugate with drugs and other substances.
TALAMAX® is a technology that enables the production of high-molecular-weight proteins such as antibodies, which have been difficult to produce using microorganisms.
In this presentation, we will introduce our one-stop-shop service from strain development to GMP manufacturing for client needs using our proprietary technologies.
|Date, Time and Venue||April 21(Fri.) 15：00-15：30 【5B】|